Patients who succumb to COVID-19 infection have higher expression of ZBP1 in their immune cells compared to non-hospitalized patients with stable COVID-19, further suggesting that there may be a pathological role for ZBP1 in driving COVID-19 severity during IFN therapy [13]. This evidence concerns the gene ZBP1 and COVID-19.